http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Ionis drug eplontersen misses primary endpoint in heart trial
-
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
-
Ionis completes enrollment in Phase 3 Angelman syndrome study
-
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
-
Ionis licenses zilganersen to Recordati for ex-U.S. markets
-
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
-
FDA approves Ionis drug Tryngolza for severe hypertriglyceridemia
-
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
-
Ionis appoints Ludwig Hantson to board of directors
-
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
-
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
-
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
-
Biogen advances IONIS alzheimer's drug after phase 2 study shows cognitive benefit
-
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer�
-
Ionis to host 2026 virtual Annual Meeting of Stockholders
-
Ionis to present at upcoming investor conferences
-
Ionis reports first quarter 2026 financial results and highlights progress on key programs
-
FDA accepts GSK's bepirovirsen for priority review in hepatitis B treatment
-
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
-
Ionis reports positive zilganersen data for Alexander disease
-
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
-
Ionis to hold first quarter 2026 financial results webcast
-
FDA grants priority review to Ionis' Alexander disease treatment
-
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
-
Ionis announces board changes with two retirements, one addition
-
Ionis announces changes to Board of Directors
-
Ionis to present DAWNZERA data at 2026 AAAAI meeting
-
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
-
FDA accepts Ionis olezarsen application for priority review
-
FDA accepts Ionis' olezarsen application for priority review
-
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
-
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
-
Ionis to present at upcoming investor conferences
-
Ionis updates time for fourth quarter and full year 2025 financial results webcast
-
Ionis to hold fourth quarter and full year 2025 financial results webcast
-
DAWNZERA gets European Commission approval for hereditary angioedema
-
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
-
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
-
GSK hepatitis B drug meets goals in phase 3 trials
-
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
-
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
-
Ionis receives FDA breakthrough therapy designation for Alexander disease drug
-
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
-
Ionis receives FDA breakthrough therapy status for severe hypertriglyceridemia drug
-
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
-
Ionis' DAWNZERA receives EU regulatory committee recommendation for HAE
-
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
-
Ionis to present at upcoming investor conferences
-
Ionis reports olezarsen cut triglyceride levels up to 72% in pivotal trials
-
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
